AC Immune SA (ACIU)
2.67
-0.02 (-0.74%)
At close: Feb 20, 2025, 3:59 PM
2.66
-0.37%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.62 |
| Market Cap | 266.15M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -6.07 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.71 |
| Volume | 155,266 |
| Avg. Volume (20D) | 155,786 |
| Open | 2.68 |
| Previous Close | 2.69 |
| Day's Range | 2.61 - 2.70 |
| 52-Week Range | 2.25 - 4.98 |
| Beta | undefined |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The comp...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2016
Employees 133
Stock Exchange NASDAQ
Ticker Symbol ACIU
Website https://www.acimmune.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 349.44% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
AC Immune SA is scheduled to release its earnings on Mar 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+13.42%
AC Immune shares are trading higher after the comp...
Unlock content with
Pro Subscription
5 months ago
+5.81%
AC Immune shares are trading higher after the company announced it will receive the second ReTain-related milestone payment under its agreement with Janssen Pharmaceuticals.
